Imhoff John E 4

What Happened

• John E. Imhoff, a reported 10% owner of Guided Therapeutics (GTHP), acquired approximately 1,589,604 common shares across several transactions between Dec 18, 2025 and Feb 27, 2026. Key components:
  • Converted convertible promissory note balances into common stock: 195,460 shares (Dec 18, 2025) for $13,682.19; 312,720 shares (Feb 2, 2026) for $21,890.41; and 156,086 shares (Feb 26, 2026) for $10,926.03 — all at $0.07 per share (total ≈ $46,498.63).
  • Exercised warrants (exchanged then exercised) resulting in 500,000 shares upon payment of $100,000.
  • Converted 100 shares of Series E preferred into 400,000 common shares (Feb 27, 2026).
  • Received 25,338 shares as payment of accrued dividends on Series E preferred (issued at a conversion price of $0.3157).
• These were net acquisitions (not open‑market purchases) largely resulting from conversions, dividend settlement in shares, and a warrant exercise — i.e., financing and conversion activity rather than typical buy/sell market trades.

Key Details

• Transaction dates and material prices:
  • 12/18/2025: 195,460 shares converted at $0.07 (≈ $13,682).
  • 02/02/2026: 312,720 shares converted at $0.07 (≈ $21,890).
  • 02/26/2026: 156,086 shares converted at $0.07 (≈ $10,926).
  • 02/25/2026: 500,000 warrants exchanged/issued at $0.20 then exercised for $100,000 (per filing).
  • 02/27/2026: 100 Series E preferred shares converted into 400,000 common shares.
  • 01/05/2026: 25,338 shares issued for accrued dividends (conversion price $0.3157).
• Cash paid (reported): ≈ $46,499 for note conversions + $100,000 for warrant exercise.
• Remaining convertible note principal after conversions: $120,000 outstanding under the September 25, 2025 note (per footnotes).
• Notable footnotes:
  • Conversions were of a Sept. 25, 2025 convertible promissory note (principal + accrued interest converted at $0.07; balance partially remains and may convert at variable price upon default).
  • Warrants were exchanged (exercise-price changes and one warrant expiration extended to 9/1/2027) before exercise.
  • 25,338 shares were issued as dividend payment on Series E preferred.
• Shares beneficially owned after these transactions are not specified in the provided summary of the filing.

Context

• These transactions are largely corporate-financing/convertible-instrument related (debt-to-equity conversions, dividend-in‑stock settlement, warrant exercise) rather than open-market purchases or gifts. Such activity often reflects capital-raising or restructuring actions rather than direct market-timing by the insider.
• As a 10% owner, Imhoff’s transactions are reported under insider rules; they are informative about capital structure changes but do not by themselves indicate personal bullish/sell intent.
• The filing documents conversion mechanics and warrant-exchange details; several derivative instruments were converted or exchanged as part of the transactions.